GSK has moved to shore up its R&D pipeline with a strategic-level deal with China's Jiangsu Hengrui Pharma that spans a dozen drug candidates and could be worth up to $12.5 billion.

Against steep odds and well-established paradigms, these four companies have successfully been commercializing their products ...

Altimmune's pemvidutide showed strong MASH resolution and good tolerability in IMPACT, but fibrosis data fell short. See why ...

How will FDA changes reshape drug approval in 2025 and beyond? Vaccines and complex biologics may face greater headwinds as processes change at a short-staffed agency ...